Gleamer vs Milvue
Both read plain radiographs across trauma and chest, both FDA cleared and assistive, both AI centrality A, so the split is evidence depth and reach against measurement breadth and deployment flexibility. If evidence depth and the broadest deployment record matter most, start with Gleamer, which grades A on clinical evidence across roughly 35 million exams and gives a graded confidence output. If you want detection plus measurements and an explicit on premise deployment, start with Milvue, accepting thinner performance reporting. Gleamer is the widest distributed fracture AI here, embedded across many imaging platforms. Milvue pairs detection with roughly 60 automatic measurements and an unusually precise account of which product is cleared where.
- The deeper evidence base and widest deployment in the fracture group: roughly 30 peer reviewed publications and 35 million exams across more than 2,000 institutions in 45 countries, against Milvue's clearance reader study and single emergency setting paper.
- A graded three tier confidence output, positive, doubt, and negative, that helps a clinician calibrate trust rather than a binary flag.
- The broadest distribution reach, embedded through many imaging platform partners including Fujifilm, so it often arrives inside a workflow already in place.
- Detection plus roughly 60 automatic measurements in one tool, where Gleamer concentrates on detection, plus a pre filled structured report returned in under 30 seconds.
- An explicit on premise deployment option alongside cloud, which Gleamer does not state as plainly and which matters for institutions keeping imaging inside their perimeter.
- Unusually precise regulatory disclosure, naming which product holds which authorization in which market and labeling its reporting module as non device software.
Side-by-Side
| Axis | G Gleamer |
M Milvue |
|---|---|---|
| AI Centrality | ||
| Autonomy and Oversight Model | ||
| Model and Technology Transparency | ||
| Clinical and Operational Evidence | ||
| AI Safety and PHI Stewardship | ||
| HIPAA and BAA Posture | ||
| Security Certifications and Trust Center | ||
| FDA and Regulatory Status | ||
| AI Governance and Bias Disclosure | ||
| EHR and Interoperability Depth | ||
| Deployment Model and Data Residency | ||
| Commercial Transparency | ||
| Setting and Specialty Coverage |
Both are FDA cleared plain radiograph detection tools spanning trauma and chest, both assistive, both French vendors selling into the US, and neither publishes pricing, a security attestation, or a business associate commitment. Milvue's performance reporting is the weaker of the two: its aggregate area under the curve above 96 percent is not broken out by pathology, region, or age, and its first place claim is unsubstantiated against a named comparator. Neither publishes a formal governance program or demographic subgroup analysis. Both distribute partly through third party imaging platforms, which adds parties to the data path and makes residency a per deployment question.